# Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

> **NCT07123350** · — · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 120 (estimated)

## Conditions studied

- Inflammatory Bowel Disease (IBD)
- Crohn&Amp;#39;s Disease (CD)
- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care

## Key facts

- **NCT ID:** NCT07123350
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123350, "Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07123350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*